FMP

FMP

Enter

TCDA - Tricida, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/TCDA.png

Tricida, Inc.

TCDA

NASDAQ

Inactive Equity

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

0.108 USD

0 (0%)

About

ceo

Dr. Gerrit Klaerner Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

CIK

0001595585

ISIN

US89610F1012

CUSIP

89610F101

Address

7000 Shoreline Court

Phone

415 429 7800

Country

US

Employee

57

IPO Date

Jun 28, 2018

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep